A new campaign from Horizon Therapeutics called Down and Out Kidney sheds light on the prevalence and impact of gout in chronic kidney disease, and aims to facilitate an important conversation with nephrologists – kidney specialists – particularly during National Kidney Month (March).
Novartis boss Vas Narasimhan expects higher sales and profitability for 2020, lifted by the company’s broad range of medicines, and minimal disruption to the Swiss drugmaker’s supply chain from the coronavirus outbreak in China.
Gilead Sciences and Eisai entered into an agreement for the distribution and co-promotion of the investigational, oral, selective JAK1 inhibitor filgotinib in Japan, pending regulatory approval for the treatment of rheumatoid arthritis (RA).
Gilead Sciences Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration for the investigational, oral, selective JAK1 inhibitor filgotinib for the treatment of adults who are living with moderate-to-severe rheumatoid arthritis.
Recently published research in the journal Nature Genetics found significant insight into this question: Why does a patient with an autoimmune disease become a type 1 diabetic rather than have rheumatoid arthritis?
China’s Bio-Thera Solutions Ltd. won a regulatory approval for the company’s version of AbbVie Inc.’s blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world’s second-largest drug market.
Pfizer Inc.’s rheumatoid arthritis drug Xeljanz could increase the risk of blood clots in the lungs and in deep veins, the European Medicines Agency (EMA) said.
Pfizer Inc. reported a higher-than-expected third-quarter 2019 profit on increased sales of the cancer drug Ibrance and a strong launch of the new heart medicine Vyndaqel.
Gilead Sciences Inc. and Galapagos NV announced that Week 52 data from the registrational Phase 3 FINCH 1 and FINCH 3 trials of filgotinib – an investigational, oral, selective JAK1 inhibitor for the treatment of moderately to severely active rheumatoid arthritis (RA) – are consistent with and support the efficacy, safety and tolerability profiles demonstrated in the Week 12 and 24 analyses presented earlier during 2019.
Swiss drugmakers Novartis and Lonza separately deepened the companies’ push into so-called biosimilars, betting cheaper copies of name-brand drugs will make headway among cost-conscious insurers and governments.